Financial Data and Key Metrics Changes - Revenue for the year increased by 82% to $6,000,000,000, driven by market share growth and the Sigma wholesale business [6][10] - Normalized EBIT rose by 41% to $835,000,000, with pro forma EBIT at $903,400,000 [6][11] - Normalized net profit after tax increased by 40% to $579,000,000, with a strong balance sheet showing net debt of $752,000,000 [6][12] - The company declared a final dividend of $0.13 per share, fully franked [7][22] Business Line Data and Key Metrics Changes - Chemist Warehouse retail network sales reached $10,000,000,000, up 14% for the year, with 35 new stores added [3][4] - Own brand portfolio grew by over 20% for the year, contributing to overall growth [4][31] - Combined distribution center volumes increased by 29% to over 530 million units, leading to a reduction in cost per unit by $0.11 [4][11] Market Data and Key Metrics Changes - The Chemist Warehouse Australian store network achieved 11.3% like-for-like sales growth [18] - International expansion included 16 new stores opened offshore, with a total of 77 stores across New Zealand, Ireland, and Dubai [29] - The company anticipates continued growth in international markets, particularly in New Zealand, where retail sales have exceeded $1,000,000,000 [29] Company Strategy and Development Direction - The company focuses on four key growth pillars: domestic growth, international expansion, product differentiation, and improved efficiencies [24][25] - Domestic growth aims to expand market leadership and pharmacy network in underpenetrated locations [26] - International expansion is seen as a growth engine, with a focus on profitable growth in existing markets [25][29] - The company has upgraded synergy targets from $60,000,000 to $100,000,000 per annum, expected to be achieved over the next four years [5][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute plans effectively, with positive momentum continuing into FY 2026 [36] - The operating environment remains competitive, particularly in the health and beauty space, but the company maintains a strong value proposition [69] - Management noted that the merger has strengthened the business, providing enhanced scale and long-term growth pathways [35] Other Important Information - The company has a conservative leverage ratio of 0.85x, indicating strong cash flows and funding capacity [12][21] - The merger accounting has resulted in an increase in goodwill by $3,600,000,000 [21] Q&A Session Summary Question: Profit contribution from Wagner's product line into 2026 - Management indicated that while there was a benefit in FY 2025, full-year benefits from Wagner's will be realized in 2026 as the product range expands [39] Question: Margin drivers for the future - Management stated that margin enhancement will come from a mix of product strategy, operational efficiencies, and growth in network scale [40] Question: Cost control and inflation outlook - Management confirmed that while some inflation is expected, the existing infrastructure allows for cost efficiencies without linear growth in costs [44][45] Question: Synergy target upgrade rationale - The upgrade to the synergy target was driven by detailed analysis post-merger, identifying multiple areas for improvement beyond just supply terms [49][50] Question: Addressing under-penetration in certain markets - Management explained that regulatory processes are in place to facilitate store openings in under-penetrated areas, with a history of successful approvals [53] Question: Expected D&A and CapEx for FY 2026 - Management expects D&A to remain consistent, with potential investments in international markets being evaluated [55][57] Question: Impact of establishing a distribution center in Ireland - Management believes that the new distribution center will positively impact profitability and support growth in the Irish market [62][64] Question: Competitive dynamics in health and beauty products - Management emphasized the company's competitive pricing and product range as key advantages over supermarkets [69] Question: Uptake of GLP-1 products - Management confirmed a material uptake in GLP-1 products, with expectations for continued growth [71] Question: Performance benchmarking in Ireland - Management indicated that turnover per store in Ireland compares favorably to New Zealand and Australia, suggesting strong growth potential [78]

Core Insights - Shiseido Group faces significant challenges, with a notable decline in performance across all regions, particularly in China and travel retail markets, which experienced double-digit drops compared to the previous year [1][2][5] Financial Performance - For the first half of 2025, Shiseido Group reported net sales of 469.83 billion yen (approximately 22.846 billion RMB), a year-on-year decrease of 7.6% [1][2] - Core operating profit increased by 21.3% to 23.372 billion yen (approximately 1.137 billion RMB), while operating profit recovered from a loss of 2.728 billion yen (approximately 133 million RMB) to 18.084 billion yen (approximately 880 million RMB) [1][2] - The decline in net sales is attributed mainly to weak performance in the Chinese and travel retail markets, as well as the impact of the Drunk Elephant brand [2][5] Market Performance - The overall net sales decline of 8% in the first half of 2025 marks the first drop for Shiseido in three years [2][5] - The Japanese market saw the smallest decline at -0.6%, while the Chinese and travel retail markets experienced the largest drop at -12.4% [2][5] - In the second quarter, all markets except for the Americas and travel retail showed low single-digit growth, with travel retail down approximately 20% [2][5] Brand Performance - The Drunk Elephant brand significantly impacted overall performance, with a 43% year-on-year decline in Q2 and a 57% drop in the first half of 2025 [10][12] - Despite challenges, the Shiseido and NARS brands showed growth when excluding the impact of the Chinese and travel retail markets, with Shiseido brand sales increasing by 4% [12][19] - The Next 5 brands, particularly ELIXIR, demonstrated double-digit growth in the second quarter and the first half of 2025 [10][12] Regional Insights - Shiseido's performance in the Chinese market is affected by economic downturns leading to low consumer spending, with offline channels continuing to decline [16][19] - The Americas market is facing challenges, particularly for the Drunk Elephant brand, while other brands like Shiseido and NARS have seen some growth [23][31] - The company has announced significant layoffs in the Americas region as part of restructuring efforts [26][31]

Core Viewpoint - MicroPort Medical's major shareholder, Otsuka Medical Devices, is selling 15.71% of its 20.70% stake, leading to a significant change in the company's ownership structure and governance [1][2]. Group 1: Shareholder Changes - Otsuka Medical Devices will reduce its stake to below 5%, exiting as the largest shareholder, while We'Tron Capital Limited will become the new largest shareholder with over 26% ownership [1]. - The transaction introduces state-owned investors, which may enhance the company's core business expansion and governance [2]. Group 2: Business Developments - MicroPort Medical is proposing a merger of its CRM business with the publicly listed company, HeartLink Medical, to create a comprehensive cardiac product platform and improve international marketing channels [2]. - The IPO for the CRM business is expected to raise at least $150 million, with a market valuation of no less than $1.5 billion [2]. Group 3: Financial Performance - For the first half of 2025, MicroPort Medical reported a revenue decline of no more than 4% (excluding currency effects) and a loss of $107 million, which is within the promised limit of $110 million [3]. - The company aims to achieve a profit of $52 million in the second half of 2025 to meet its convertible bond financing agreement requirements [3]. - Revenue projections for 2025-2027 are estimated at $1.193 billion, $1.393 billion, and $1.595 billion, with net profits of -$48 million, $83 million, and $159 million respectively [3].

Investment Rating - The report assigns a "Buy" rating to the company, indicating an expected stock price increase of over 15% within the next six months [5]. Core Views - The report highlights the strategic restructuring of major shareholders, with the exit of the previous largest shareholder, Otsuka Medical, and the entry of state-owned investors, which is expected to enhance business expansion and governance [1]. - The proposed merger of the CRM business with another listed company aims to create a comprehensive cardiac product platform, enhancing international marketing channels and synergy [2]. - The company is on track to meet its profit commitments for the first half of 2025, with expectations for continued improvement in profitability in the second half [2]. Financial Summary - Revenue projections for 2025-2027 are estimated at $1.193 billion, $1.393 billion, and $1.595 billion, respectively, with a net profit forecast of -$47.5 million, $82.62 million, and $158.87 million [3][10]. - The company is expected to achieve a significant turnaround in profitability, with a projected net profit margin of 5.9% by 2026 and 10.0% by 2027 [10]. - The report outlines a gradual improvement in earnings per share (EPS), moving from -0.12 in 2024 to 0.09 in 2027 [10]. Market Data - As of July 28, 2025, the closing price of the stock was HKD 11.58, with a market capitalization of approximately HKD 21.43 billion [5]. - The stock has shown strong performance with absolute returns of 34% over one month, 72% over three months, and 120% over twelve months [7].

Core Viewpoint - The merger between Hino Motors and Mitsubishi Fuso aims to enhance competitiveness in R&D, procurement, and production within the commercial vehicle sector [1][5]. Group 1: Merger Details - Hino and Mitsubishi Fuso will establish a holding company headquartered in Tokyo, with both companies becoming wholly-owned subsidiaries of the new entity [3]. - Daimler Trucks and Toyota will each hold a 25% stake in the new company, which will employ over 40,000 people, with Karl Deppen from Mitsubishi Fuso serving as CEO [3]. Group 2: Factory Transfer - Hino announced the transfer of its vehicle and parts factory located in Hamura, Tokyo, to Toyota, which has been operational since 1963, primarily producing small trucks for both Hino and Toyota brands [4]. Group 3: Previous Agreements - The four companies had reached a preliminary agreement in May 2023 to merge their commercial vehicle operations by the end of 2024, but the final agreement was delayed indefinitely due to Hino's engine certification fraud issue [5].

As filed with the Securities and Exchange Commission on March 8, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EUREKA ACQUISITION CORP (Exact name of registrant as specified in its charter) ___________________ Cayman Islands 6770 N/A (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) ...

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 19, 2023 Registration No. 333-275521 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SPORTSMAP TECH ACQUISITION CORP.* (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 3827 (Primary Standard Industrial Classification Code Number) 5353 West Ala ...

Table of Contents As filed with the Securities and Exchange Commission on December 12, 2023 Registration No. 333-275521 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SPORTSMAP TECH ACQUISITION CORP.* (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) Copies to: Ralph V. De Martino ArentFox Schiff LLP 1717 K Street NW Washing ...